Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rongqing Baohua suppository powder is a Traditional Chinese Medicine (TCM) formulation developed by Qilu Hospital of Shandong University. It is primarily investigated for the treatment of carotid atherosclerosis and hyperlipidemia. In clinical studies, it is typically evaluated as an adjunct to standard statin therapy, such as atorvastatin, to assess its efficacy in reducing carotid atherosclerotic plaque volume and lowering low-density lipoprotein cholesterol (LDL-C) levels. As a TCM product, it is likely composed of multiple botanical ingredients that exert therapeutic effects through multi-target modulation of lipid metabolism and vascular inflammatory pathways. The formulation is administered rectally.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Rongqing Baohua suppository powder.